The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for two new formulations of ViiV ...

UK MHRA grants marketing approval for ViiV Healthcare’s cabotegravir formulations to help prevent HIV-1 infection in adults and adolescents: United Kingdom Saturday, May 4, 2024 ...

A decade-long collaboration between Viiv Healthcare and the Medicines Patent Pool (MPP), and Viiv’s direct agreements with Aurobindo Pharma have enabled 24 million people to access dolutegravir (DTG), ...

Ten years after the signing of ground-breaking licensing agreements between ViiV Healthcare and the Medicines Patent Pool ...

ViiV Healthcare and Exavir Therapeutics ended a lawsuit over allegations that Exavir’s patent-licensing agreement with the University of Nebraska on long-acting HIV therapy compounds interfered with ...

The license is designed so that tens of thousands of Colombians can obtain a lower-cost version of dolutegravir, a medicine that is manufactured and sold by ViiV Healthcare, a company that ...

Months before that, ViiV Healthcare rolled out Backseat Hotseat, a campaign to normalize conversations about HIV prevention, with the help of comedians Phoebe Robinson and Matteo Lane. Over the course ...

head of North America at ViiV Healthcare, said in a statement. Approval of Dovato was granted to ViiV Healthcare.

ViiV Healthcare today announced results from an interim analysis of the LATITUDE Phase III trial, indicating its long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + ...

J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).